CrowdStrike stock slides after-hours as Wedbush keeps CRWD on its top AI picks list

CrowdStrike stock slides after-hours as Wedbush keeps CRWD on its top AI picks list

NEW YORK, January 1, 2026, 14:48 ET — Market closed

  • CrowdStrike last traded at $468.76, down 1.5% from its prior close, with U.S. markets shut for the New Year’s Day holiday.
  • Wedbush’s Dan Ives reiterated a bullish 2026 view on CrowdStrike, keeping a $600 price target in a client note.
  • Cybersecurity peers and sector ETFs also dipped into year-end.

CrowdStrike Holdings, Inc. shares were last down 1.5% at $468.76 in extended trading after closing at $475.69 on Wednesday, as U.S. markets paused for the New Year’s Day holiday. New York Stock Exchange

The move matters now because investors are resetting positions into the first trading day of 2026, with high-growth software and cybersecurity names still sensitive to shifts in risk appetite.

CrowdStrike is a bellwether in endpoint security, and its valuation leaves little room for execution slips. Any change in expectations for subscription growth or margins can move the stock sharply.

Wedbush Securities analyst Dan Ives said in a note to clients that CrowdStrike “remains one of our favorite tech names,” while keeping a $600 price target and positioning the company as a beneficiary of AI-driven security spending. Business Insider

CrowdStrike’s late dip tracked a softer tape across tech and cybersecurity. The Invesco QQQ Trust (QQQ) was down 0.8%, while the Amplify Cybersecurity ETF (HACK) and First Trust Nasdaq Cybersecurity ETF (CIBR) each fell about 1.1% in the last trade.

Among large peers, Palo Alto Networks and Fortinet were also lower into the close, down about 1.4% and 1.1% respectively.

CrowdStrike’s latest catalyst remains its early-December quarterly update, when the company forecast stronger-than-expected fourth-quarter revenue and raised its full-year revenue outlook, pointing to demand for AI-integrated tools on its Falcon platform. Reuters

Investors have also kept an eye on customer retention after a faulty software update last year triggered widespread system outages, prompting the company to offer incentives that weighed on subscription metrics, Reuters has reported. Reuters

A key metric to watch in the next results is ARR, or annual recurring revenue — a common measure of subscription revenue run-rate. Traders also track “net new ARR,” which shows how much new subscription business the company added in a quarter.

Technically, the stock’s near-term markers sit around Wednesday’s session range: support near $468 and resistance around $477, based on the day’s low and high.

With markets reopening on Friday, investors will also look ahead to early-January U.S. data that can sway rate expectations and tech multiples, starting with the next ISM manufacturing report scheduled for 10:00 a.m. ET on Monday, Jan. 5. Institute for Supply Management

Beyond that, the U.S. jobs report for December is due on Jan. 9, followed by the December consumer price index on Jan. 13, according to the Labor Department’s release schedule. Bureau of Labor Statistics

CrowdStrike’s next earnings date has not been confirmed by the company, but earnings calendars such as Zacks list the next report for March 3, after the fiscal quarter ends Jan. 31. Investors will be watching for updated revenue growth expectations and any commentary on demand trends heading into fiscal 2027. Zacks+1

Stock Market Today

  • Halozyme beats Q3 CY2025 revenue, EPS; raises 2025 guidance on ENHANZE
    January 1, 2026, 4:40 PM EST. Halozyme Therapeutics (NASDAQ: HALO) reported Q3 CY2025 results that beat revenue and earnings expectations. Revenue reached $354.3 million, up 22.1% year over year and about 3.1% above consensus. The company reaffirmed a full-year revenue guide of $1.34 billion at the midpoint, roughly 1.5% above estimates. Non-GAAP EPS was $1.72, a 5.5% beat; EBITDA totaled $238.3 million with a 67.3% margin. Operating margin rose to 61.5% from 56.3% a year earlier, and free cash flow margin climbed to 49.6%. Halozyme's ENHANZE technology, enabling subcutaneous delivery of injectable drugs, remains a key growth driver. Looking ahead, analysts see about 28.1% revenue growth over the next 12 months.
GE Aerospace stock slips into 2026 as Wall Street shuts for New Year’s Day
Previous Story

GE Aerospace stock slips into 2026 as Wall Street shuts for New Year’s Day

Applied Materials stock dips as new U.S. export licenses and China’s 50% tool rule reset focus for AMAT
Next Story

Applied Materials stock dips as new U.S. export licenses and China’s 50% tool rule reset focus for AMAT

Go toTop